Cost-effectiveness analysis of ixekizumab versus secukinumab in patients with psoriatic arthritis and concomitant moderate-to-severe psoriasis in Spain

Objective To conduct a cost-effectiveness analysis from the perspective of the Spanish National Health System (NHS) comparing ixekizumab versus secukinumab.Design A Markov model with a lifetime horizon and monthly cycles was developed based on the York model. Four health states were included: a biol...

Full description

Saved in:
Bibliographic Details
Main Authors: Susanne Hartz, Christophe Sapin, Bernd Schweikert, Chiara Malmberg, Mercedes Núñez, Tatiana Dilla
Format: Article
Language:English
Published: BMJ Publishing Group 2020-08-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/10/8/e032552.full
Tags: Add Tag
No Tags, Be the first to tag this record!